India Gears Up To Monitor Safety Of New Drugs; Launches Nationwide Pharmacovigilance Program
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - At a time when GlaxoSmithKline's anti-diabetes drug Avandia has come under serious fire over its long-term cardiovascular safety profile, India's Central Drugs Standard Control Organization has launched an ambitious pharmacovigilance program for monitoring safety of newly introduced medicines